Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma

作者：Fang‐Zhu Ouyang, Ruiqi Wu, Wei Yuan, Ruixian Liu, Dong Yang, Christos Xiao, Limin Zheng, Bo Li, Xiang‐Ming Lao, Dong‐Ming Kuang · 发表于：Nature Communications · 年份：2016 · DOI：10.1038/ncomms13453 · 被引用次数：105 · 研究领域：Immunotherapy and Immune Responses、Monoclonal and Polyclonal Antibodies Research、Immune Cell Function and Interaction

Abstract B cells are prominent components of human solid tumours, but activation status and functions of these cells in human cancers remain elusive. Here we establish that over 50% B cells in hepatocellular carcinoma (HCC) exhibit an FcγRII low/− activated phenotype, and high infiltration of these cells positively correlates with cancer progression. Environmental semimature dendritic cells, but not macrophages, can operate in a CD95L-dependent pathway to generate FcγRII low/− activated B cells. Early activation of monocytes in cancer environments is critical for the generation of semimature dendritic cells and subsequent FcγRII low/− activated B cells. More importantly, the activated FcγRII low/− B cells from HCC tumours, but not the resting FcγRII high B cells, without external stimulation suppress autologous tumour-specific cytotoxic T-cell immunity via IL-10 signals. Collectively, generation of FcγRII low/− activated B cells may represent a mechanism by which the immune activation is linked to immune tolerance in the tumour milieu.